NEWSROOM
News
Announcements, media coverage and milestones from De Motu Cordis.
Meet our new Chief Operating Officer, Ludo Bonnet
In an industry often defined by compliance and incremental progress, Ludovic “Ludo” Bonnet has built a career on moving with both precision and pace.
Unlock the MRFF – Professor John Fraser AO Joins Call for Action on Medical Research Funding
De Motu Cordis Founder and Chief Medical Officer, Professor John Fraser AO, is among more than 60 of Australia’s most eminent scientists and industry leaders calling on the federal government to unlock the Medical Research Future Fund (MRFF).
Redefining What’s Possible in Emergency Drug Delivery
At the demanding intersection where innovation meets commercial reality, DMC’s Legal Counsel, Sonia Barber stands out as a leader who speaks fluently across law, business, science and global strategy.
Steady hands at the helm: John Corbett to guide DMC into next chapter
As DMC prepares for the critical step of entering clinical trials, we have appointed John Corbett as Interim CEO. John brings considerable business acumen and strategic skills to the role, having served as our CFO for 5 years.
DMC wins Radium Capital Emerging Innovator Award AT 2025 LSQ GENE AWARDS
On Friday 12 September, DMC was awarded the Radium Capital Emerging Innovator Award at the 2025 Life Sciences Queensland (LSQ) GENE Awards, held in Brisbane.
Professor John Fraser AO Presents at the Food Allergy Fund Innovation & Investment Summit
In April 2025, Professor John Fraser AO, Founder and Chief Medical Officer of DMC had the privilege of presenting at the prestigious Food Allergy Fund Summit in New York.
Innovating Emergency Care | Peter O’Neill Discusses De Motu Cordis at JPM Week 2025
During the prestigious JPM Week 2025, held at San Francisco’s Golden Gate Yacht Club, Peter O’Neill, CEO of De Motu Cordis, engaged in a compelling conversation with James Zanewicz of Tulane University School of Medicine.
De Motu Cordis Highlighted in Two Page Feature in the Courier Mail
De Motu Cordis are proud to be featured in the Saturday edition of the Courier Mail (March 15th, 2025).
Children with Anaphylaxis Who Receive Epinephrine Before Hospital Are Much Less Likely to Need ICU
Children with Anaphylaxis Who Receive Epinephrine Before Hospital Are Much Less Likely to Need ICU
De Motu Cordis Expands Global IP Portfolio
Leading into J.P. Morgan Healthcare Week, De Motu Cordis (DMC) is pleased to announce the continued growth of our global intellectual property (IP) portfolio, now encompassing 29 granted patents across six patent families.
De Motu Cordis (DMC) receives a letter of support from Food Allergy Research and Education (FARE)
On November 1, 2024, DMC received a formal letter of support from Food Allergy Research and Education (FARE), the largest nonprofit organisation in the U.S. committed to enhancing the quality of life and health for individuals with food allergies through innovative research, education, and advocacy.
De Motu Cordis (DMC) Applauds ARS Pharma’s FDA Approval of Neffy®, Expanding Patient Options to Needle-Free Epinephrine Delivery and Inspiring Confidence in Our Own Development Efforts.
De Motu Cordis (DMC) is pleased to acknowledge and enthusiastically commends the recent U.S. FDA approval of ARS Pharma’s Neffy®, the first-ever needle-free intranasal epinephrine delivery device for the treatment of anaphylaxis.
